19 results about "P53 Mutation" patented technology

Mutations in oncogenes and tumor suppressor factors contribute to the development and progression of cancer. This disclosure describes compounds and methods for restoring DNA-binding affinity of p53 mutants, as well as their use in diagnostic assays to guide the treatment of subjects with said compounds for cancer. The compounds of this disclosure can bind to mutant p53 and restore the ability of p53 mutants to bind to DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers containing p53 mutations.

The invention belongs to the technical field of biomedicine, and particularly relates to application of ADH-6 in preparation of a medicine for treating prostatic cancer. The invention provides application of ADH-6 in preparation of a product for preventing, relieving or / and treating prostatic cancer. The ADH-6 specifically targets the prostatic cancer with p53 mutation, the p53 mutation comprises p53 contact mutation and p53 structural mutation, the conformation of the p53 mutation is remodeled to restore the transcriptional activity of the wild type p53, the expression of downstream target genes P21CDKN1A, BAX and PUMA of the p53 is enhanced, and finally, the proliferation of the prostatic cancer cells is inhibited, and the apoptosis of the prostatic cancer cells is promoted.

Provided are a compound for recovering a p53 mutation function and use thereof, particularly relating to a compound represented by Formula M, or an enantiomer, a diastereomer, a racemate, a tautomer, a stereoisomer, a geometric isomer, a crystal form, a nitrogen oxide, a metabolite or pharmaceutically acceptable salt, ester, solvate, hydrate, isotope-labeled compound or prodrug of the compound.

Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes methods of recovering wild-type function to p53 mutants by treating a tumor with a compound and a second agent. The compounds of the present invention can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used in combination with an MDM2, PI3K, or AKT inhibitor to reduce the progression of cancers that contain a p53 mutation.

Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. Disclosed herein are compounds and methods to recover wild-type function of p53 mutants using x-ray co-crystal structures of mutant p53 and compounds of the disclosure. The compounds of the present invention can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.

Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants. The compounds of the present invention can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.

Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants. The compounds of the present invention can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.

Mutations in oncogenes and tumor suppressor genes contribute to the development and progression of cancer. The present disclosure describes compounds and methods for restoring wild-type function to p53 mutants. The compounds of the invention can bind to mutant p53 and restore the ability of p53 mutants to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers containing p53 mutations.

The invention discloses a new fused ring or large heterocyclic ring compound with a P53 signal channel abnormity regulation effect, and particularly discloses a compound which is used as a P53 mutation target spot regulator and has a structure shown in a formula (I) or pharmaceutically acceptable salt, solvate, hydrate, isotope substitute or isomer thereof.

The present invention discloses a tetravalent platinum complex containing APR-246, having a structure as shown in Formula I: wherein n is selected from 0, 1, 2, 3, or 4; R is selected from a branched or linear C1-C20 alkyl group; and R2 is selected from a branched or linear C1-C20 alkyl group. The tetravalent platinum compounds containing the p53 mutation activator APR-246 provided by the present invention can enhance the anti-tumor activity of APR-246 and leverage the anti-tumor advantages of APR-246 and divalent platinum drugs. By utilizing the unique anti-tumor mechanism of APR-246, they can work together with platinum drugs to achieve excellent synergistic anti-tumor efficacy, while also significantly helping to improve tumor drug resistance.

The present disclosure relates to compounds and methods to restore wild-type function of p53 mutants and to treat proliferative disorders or cancers associated with p53 mutation.

Prodigiosin analogs which reactivate the p53 pathway are provided, as well as compositions of these compounds, and methods for reactivation of the p53 pathway using these compounds are provided. The prodigiosin analogs may be used to treat cancer in which p53 mutation plays a role, including prostate cancer, breast cancer, kidney cancer, ovarian cancer, lymphoma, leukemia, and glioblastoma, among others.

The invention relates to the technical field of image processing, in particular to a P53 mutation classification method and system for an endometrial cancer pathological section, and the method comprises the steps: carrying out the cutting of a full-view section of endometrial tissue, obtaining a plurality of image blocks, and recording the initial position information of the image blocks; performing feature extraction on each image block to obtain a feature vector of each image block; inputting all the feature vectors and the initial position information into a feature classification model to obtain a corresponding classification result; the feature classification model is used for performing sequence splicing on the feature vectors and inserting a category token to obtain a feature sequence; extracting context information of the feature sequence, and performing multi-scale feature extraction on the context information to obtain a multi-scale comprehensive vector; and obtaining a corresponding classification result based on the multi-scale comprehensive vector and all the initial position information. According to the embodiment of the invention, related personnel can be assisted to more accurately judge whether P53 mutation occurs in the endometrial cancer pathological section or not.

Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants. The compounds of the present invention can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression or incidence of cancers that contain a p53 mutation.

The invention relates to blocking of IL-34 signal as an immunotherapy for p53 mutant liver cancer. Specifically, the invention relates to application of an IL-34 inhibitor in preparation of a medicine or a kit for treating p53 mutation liver cancer. On the other hand, the invention further relates to application of the IL-34 inhibitor and the anti-PD-1 antibody to preparation of a medicine or a kit for treating the p53 mutation liver cancer.

Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants. The compounds of the present invention can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.

Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods that restore DNA binding affinity of p53 mutants. The compounds of the present disclosure can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.

The present disclosure relates to compounds and methods to restore wild-type function of p53 mutants and to treat proliferative disorders or cancers associated with p53 mutation. Formula (O)